Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HNSCC
Open-data reference.
24 US clinical trials · 16 currently recruiting
Active & Recent Trials
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
University Hospital Freiburg
NCT05337631
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
NCT03526835
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
SparX Biotech(Jiangsu) Co.
NCT06259552
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology
NCT07085091
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Epkin
NCT06789172
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Vanderbilt-Ingram Cancer Center
NCT06915454
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
VLP Therapeutics
NCT06736379
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT04722523
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
University of California, Irvine
NCT06693323
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ImmVira Pharma Co.
NCT04370587
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
NCT06819228
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
University of Cincinnati
NCT04340258
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
NCT05980000
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
AgonOx
NCT05902520
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03082534
De-Escalation Therapy for Human Papillomavirus Negative Disease
University of Chicago
NCT03944915
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
University of Colorado, Denver
NCT04042935
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 16 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the HNSCC Trial Landscape
ClinicalTrials.gov lists 24 US studies indexed under HNSCC, and 16 of those are currently open to recruitment — roughly 67% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for HNSCC shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 21 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for HNSCC is led by Dan Zandberg with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 24 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for HNSCC?
PlainTrial tracks 24 US clinical trials for HNSCC, of which 16 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HNSCC?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.